Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MARK2 pseudogene 17 (MARK2P17) is a human pseudogene, characterized as a non-functional genomic sequence homologous to the protein-coding MARK2 gene (Microtubule Affinity Regulating Kinase 2). Pseudogenes typically do not encode functional proteins; instead, some may be transcribed as non-coding RNAs and act through regulatory mechanisms such as miRNA sponging, antisense transcript formation, or competing endogenous RNA (ceRNA) networks. MARK2P17 itself has not been identified as a therapeutic target, nor are there any drugs or disease roles directly associated with it. Its designation as a pseudogene means it is generally not the focus of drug discovery or biomarker development, and no protein product or classic receptor/enzyme function exists for MARK2P17. If you are interested in the canonical biological target, refer to Microtubule Affinity Regulating Kinase 2 (MARK2), a serine/threonine kinase involved in cell polarity and microtubule dynamics.
Not applicable (no direct protein product or established role)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MARK2 pseudogene 17 (MARK2P17).